Last R$73.18 BRL
Change Today 0.00 / 0.00%
Volume 0.0
PFIZ34 On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 3:02 PM 09/29/14 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc - bdr (PFIZ34) Snapshot

Open
R$73.22
Previous Close
R$73.18
Day High
R$73.22
Day Low
R$73.18
52 Week High
02/12/14 - R$77.18
52 Week Low
10/10/13 - R$61.64
Market Cap
466.1B
Average Volume 10 Days
5.6K
EPS TTM
--
Shares Outstanding
6.4B
EX-Date
07/30/14
P/E TM
--
Dividend
R$2.33
Dividend Yield
3.19%
Current Stock Chart for PFIZER INC - BDR (PFIZ34)

pfizer inc - bdr (PFIZ34) Details

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company’s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company’s Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd. to develop population health management platform with advanced analytics and patient care capabilities. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

77,700 Employees
Last Reported Date: 02/28/14
Founded in 1849

pfizer inc - bdr (PFIZ34) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.2M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.1M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $926.3K
Group President of Global Established Pharma ...
Total Annual Compensation: $810.1K
Compensation as of Fiscal Year 2013.

pfizer inc - bdr (PFIZ34) Key Developments

Pfizer and Kyowa Hakko Kirin to Collaborate on Immuno-Oncology Combination Study

Pfizer Inc. and Kyowa Hakko Kirin announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab, which suppresses some of the immune cells that shield the tumor from the immune system, in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors. Under the terms of the agreement, Pfizer and Kyowa Hakko Kirin will co-fund the clinical study, which will be conducted by Pfizer. This study is expected to establish a recommended dose regimen and assess the safety and preliminary efficacy of the combination. This study is expected to begin in 2015 and the results will determine the future clinical development of the combination.

Pfizer Reportedly Eyes To Acquire Actavis

Pfizer Inc. (NYSE:PFE) has approached Actavis plc (NYSE:ACT) to express its interest in an acquisition, people with knowledge of the matter said. The companies aren’t currently in formal talks and Pfizer hasn’t made an offer, the people said, asking not to be identified because the information is private. Representatives for Pfizer and Actavis declined to comment.

Circle Pharma, Inc. Initiates Two Collaborations with Pfizer Inc. to Develop Cell Permeable Macrocyclic Peptide Therapeutics

Circle Pharma, Inc. announced that the company has initiated two collaborations with the company to develop cell permeable macrocyclic peptide therapeutics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFIZ34:BZ R$73.18 BRL 0.00

PFIZ34 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €110.68 EUR -0.026
Merck & Co Inc $59.28 USD -0.13
Novartis AG SFr.90.15 CHF +1.05
Roche Holding AG SFr.283.10 CHF +2.40
Sanofi €89.56 EUR +1.95
View Industry Companies
 

Industry Analysis

PFIZ34

Industry Average

Valuation PFIZ34 Industry Range
Price/Earnings 18.8x
Price/Sales 3.8x
Price/Book 2.5x
Price/Cash Flow 12.8x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC - BDR, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.